With a resurgence of COVID-19 cases underway and a second wave of infections on the horizon, the health and economic threats the pandemic poses are not going away any time soon.
The crisis has triggered clinical trial delays for many manufacturers of pharmaceutical products, while others have rallied around the COVID-19 pandemic, with as many as 417 Phase 2 and Phase 3 industry-sponsored trials ongoing and another 285 registered but not yet recruiting.
Whether developing treatments to address the pandemic or trying to keep other development pipelines ﬂowing, the industry must now contend with a variety of new commercialization and marketing challenges.
In this article Molly Hoult talks about:
- Commercialization Challenges for COVID-19 Therapeutics
- Commercial Delays for Non-COVID-19 Indications
- Sales and Marketing Challenges and Opportunities
Download the complete White Paper: